www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion Innovations investee WellGen in food product collaboration with RFI Ingredients
Amphion Innovations PLC (AIM: AMP) said WellGen Inc, in Which it holds a 14.6 percent stake, is entering a collaboration with RFI Ingredients develop proprietary medical food, functional food, and dietary supplement products.
The companies have signed a memorandum of understanding that serves as a framework for collaboration on several high-growth opportunities: the creation of new medical foods for people with inflammation-related diseases for which there are major unmet needs; the creation of new dietary supplement and functional food products for consumer and health care professional markets; and the development and supply of natural ingredients with strong scientific and clinical support.
WellGen uses proprietary biotechnology methods and the understanding of natural products chemistry to develop and distinguish natural materials which they market in products for therapeutic purposes. WellGen is focused on inflammation-related disease for their medical food products and is currently working on a new medical food for diabetes. RFI Ingredients is a manufacturer of natural ingredients.
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
Amphion’s investments also include 38.5 percent in Motif Biosciences, a 19.99 percent stake in Kromek, 20 percent in Myconostica Ltd, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp, 25 percent in Private Markets and 100 percent in DataTern.
